• NOXXON to Launch NOX-A12 with Radiotherapy Clinical Trial in Patients with Brain Cancer

    • November 22, 2018
    • Posted By : admin
    • 0 Comment
    •   68 views

    NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the Company is preparing a new clinical trial combining NOX-A12 with radiotherapy for the treatment of patients with newly diagnosed brain tumors. The combination of NOX-A12 and radiotherapy has the potential for wide application as a cancer therapy.

    NOXXON plans to perform a dose escalation trial of NOX-A12 plus radiotherapy in primary brain cancer patients who would not benefit medically from standard of care chemotherapy. The aim of this study is to establish the safety and tolerability profile and define the recommended Phase 2 dose of NOX-A12 in combination with radiotherapy as well as assess signals of efficacy including changes in tumor vascularization, progression-free and overall survival.

    “It is known that radiotherapy kills blood vessels supplying tumors. The problem is that the tumor regrows vessels rapidly thanks to cells recruited from the bone marrow in a process called vasculogenesis, but we can block the recruitment of these “repair” cells with NOX-A12,” said Dr. Jarl Ulf Jungnelius, CMO of NOXXON Pharma. “With the clinicians who will run this dose-escalation trial, we are convinced that this approach will provide significant benefit for patients once the dose and therapy duration are optimized. We aim to initiate the trial in the second quarter of 2019.”

  68 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!